Initial treatment outcome and feasibility of low-dose cabazitaxel against docetaxel- and castration-resistant prostate cancer in a Japanese hospital
| Autor: | Takahiro Yasui, Yoshinobu Moritoki, Takashi Nagai, Daichi Kobayashi, Takahiro Yanase, Ryosuke Chaya, Takehiko Okamura, Hidetoshi Akita |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
030222 orthopedics
medicine.medical_specialty castration resistant prostate cancer cabazitaxcel Anemia business.industry Neutropenia medicine.disease prostate cancer Gastroenterology Dysgeusia 03 medical and health sciences Prostate cancer 0302 clinical medicine Docetaxel Cabazitaxel Internal medicine medicine Original Article 030212 general & internal medicine medicine.symptom Adverse effect business Febrile neutropenia medicine.drug |
| Zdroj: | Journal of Rural Medicine : JRM |
| ISSN: | 1880-487X |
| Popis: | Introduction: Cabazitaxel (CBZ) is used worldwide for castration-resistant prostate cancer after docetaxel treatment. In July 2014 the drug was approved in Japan with the same induction dose used for Caucasian patients. In this study, we examined and compared the results of an initial low-dose CBZ treatment in patients admitted to our hospital. Patients and Methods: Between July 2014 and August 2018, sixteen mCRPC patients were enrolled and underwent a low-dose CBZ treatment at our hospital. We compared the results with those of a Japanese metastatic docetaxel- and castration-resistant prostate cancer Phase I study. Results: The median patient age was 77 years (range, 53-84 years). Of the 16 patients, eight (50%) had a lymph node metastasis and 11 (68.8%) had a distant metastasis, 10 of whom had only a bone metastasis. The median dose of CBZ was 30 mg (range, 20-32 mg) and the median number of CBZ cycles was 2.5 (range, 1-18). The PSA level of 9 (56.3%) patients decreased after CBZ treatment, including 4 (25%) who showed a decrease to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|